Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to assess the feasibility, acceptability, and potential effects of therapist-guided internet-delivered cognitive-behavior therapy (iCBT) for adult obsessive-compulsive disorder, using a recently developed digital platform.
Although cognitive-behavior therapy (CBT) is a well-established first-line treatment for many mental disorders, very few patients receive it due to the shortage of trained professionals, the costs of face-to-face therapy, and geographic barriers. Therapist-guided internet-delivered CBT (iCBT) is a potential solution to this problem but is not generally available in our context.
The investigators plan to:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Internet-delivered Cognitive Behavioral Therapy (iCBT) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| icbt | Behavioral | 12-Week Therapist-Based iCBT for OCD (Adapted Version of OCD Net: https://therapistguide.webcbt.se/index.html) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility (recruitment and retention rates and therapist burden) | The investigators will assess feasibility by recording recruitment rates, retention rates, and therapist burden (time spent by the therapist sending emails, reviewing materials, etc.). | From enrollment to the end of treatment at 12 weeks |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Acceptability (Treatment Acceptability/Adherence Scale, TAAS) | The TAAS assesses satisfaction with treatment and adherence. | Immediately after the intervention |
| Yale-Brown Obsessive-Compulsive Scale | The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) evaluates the severity of obsessive-compulsive disorder symptoms in adults. It is a clinician-rated, 10-item scale, with each item rated from 0 (no symptoms) to 4 (extreme symptoms), resulting in a total score ranging from 0 to 40. The scale also provides separate subtotals for the severity of obsessions and compulsions. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Miquel A Fullana, PhD | Contact | 34+637908990 | mafullana@clinic.cat | |
| Maria Sagué, MD | Contact | 34 +932 27 54 00 | msague@clinic.cat |
| Name | Affiliation | Role |
|---|---|---|
| Joaquim Radua, MD | Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009771 | Obsessive-Compulsive Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Single-Group Assignment
Not provided
Not provided
Not provided
Not provided
| Baseline and 12 weeks |
| Clinical Global Impression (CGI)-Severity | The CGI rates the severity of the patient's illness at the time of assessment on a 7-point scale, from 1 = normal to 7 = among the most extremely ill patients. | Baseline and 12 weeks |
| Beck Depression Inventory | The BDI assesses the severity of depressive symptoms in adolescents and adults. | Baseline and 12 weeks |
| Negative Effects Questionnaire (NEQ) | The NEQ assesses potential negative side effects of the intervention. | Baseline, mid-intervention and 12-weeks |
| Obsessive-Compulsive Inventory Revised (OCI-R) | The OCI-R assesses obsessive-compulsive symptoms experienced over the past month. It is an 18-item self-report questionnaire covering six symptom dimensions: washing, checking, ordering, obsessing, hoarding, and neutralizing. Each item is rated on a 5-point scale (0 = not at all, 4 = extremely), reflecting the distress caused by the symptom during the past month. | Baseline and after 12 weeks |